#USA #New York #Securities Class Action #Faruqi #Unicycive

Overview

Faruqi & Faruqi, LLP has announced an investigation into potential claims on behalf of investors of Unicycive Therapeutics, Inc. This comes on the heels of pressing concerns regarding the company's ability to comply with FDA manufacturing standards. Investors who suffered losses in Unicycive Therapeutics and acquired securities between March 29, 2024 and June 27, 2025 are urged to reach out to the firm for guidance regarding their rights and possible legal avenues.

Background of the Investigation

Based in New York, Faruqi & Faruqi is known for its dedication to serving investors and has successfully recovered significant sums on behalf of its clients since its establishment in 1995. The firm is currently focusing its attention on Unicycive following several troubling disclosures that have negatively impacted the stock price of the company. The purpose of this investigation is to determine whether Unicycive's executives made false or misleading statements regarding their compliance with FDA regulations, which led to substantial financial losses for investors.

Allegations Against Unicycive Therapeutics

According to the complaint being investigated, there are serious allegations against Unicycive Therapeutics. The company reportedly overstated its readiness to meet FDA manufacturing compliance requirements. Specific claims involve assertions related to the NDA (New Drug Application) process for a treatment aimed at managing hyperphosphatemia in patients with chronic kidney disease undergoing dialysis.

1. Misstatements on Compliance: Unicycive's executives allegedly misrepresented the status of their manufacturing compliance capabilities.
2. Overrated Regulatory Prospects: Statements suggesting positive potential regulatory outcomes from the FDA were believed to be overstated.
3. Failure to Disclose: The firm’s failure to fully disclose significant manufacturing deficiencies identified during an FDA inspection raised alarms for investors who relied on these statements when making investment decisions.

These alleged failings culminated in major drops in Unicycive's stock price following public disclosures about non-compliance. On June 10, 2025, following the announcement of compliance issues from the FDA, the company witnessed a decrease in share value by 40.89%. Furthermore, additional regulatory setbacks announced on June 30, 2025 led to another drop of 29.85%.

Call to Action for Investors

With a deadline of October 14, 2025 fast approaching, investors who believe they might be affected are encouraged to consider their options for joining the federal securities class action against Unicycive. Being a lead plaintiff in such cases allows a person to steer the litigation on behalf of the impacted investors. Investors are not pressured to take on this role; they have the option to remain absent class members, but they may still be eligible for recovery under the class actions.

Faruqi & Faruqi's partner, James (Josh) Wilson, emphasizes the importance of acting quickly and invites all potential claimants to reach out directly for tailored advice. He is reachable at 877-247-4292 or 212-983-9330.

Conclusion

The investigation into Unicycive Therapeutics reflects ongoing challenges within the pharmaceutical industry regarding adherence to regulatory expectations and the imperatives of transparent communications with investors. As this case unfolds, it serves as a critical reminder to investors to stay vigilant about the companies they support and the executive claims made concerning their operational capacities. Interested parties such as whistleblowers, former employees, and shareholders who have insight into Unicycive's conduct are also encouraged to reach out, contributing to a more complete understanding of the situation.

For more information about the Unicycive Therapeutics class action, visit www.faruqilaw.com/UNCY.